Literature DB >> 15226408

CD9-mediated activation of the p46 Shc isoform leads to apoptosis in cancer cells.

Yoko Murayama1, Jun-ichiro Miyagawa, Kenji Oritani, Hitoshi Yoshida, Katsumi Yamamoto, Osamu Kishida, Tamana Miyazaki, Shusaku Tsutsui, Tatsuya Kiyohara, Yoshiji Miyazaki, Shigeki Higashiyama, Yuji Matsuzawa, Yasuhisa Shinomura.   

Abstract

CD9, a member of the tetraspanin family, has been shown to be involved in a range of cellular activities, including migration, proliferation and adhesion, but the molecular mechanisms by which it mediates such events is unclear. Here, we found that anti-CD9 monoclonal antibody ALB6 inhibited cell proliferation, reduced cell viability and induced not only morphological changes specific to apoptosis but also molecular changes, as evidenced by TUNEL and annexin-V staining. For the possible mechanism of ALB6-induced apoptosis, ALB6 activated the c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 mitogen-activated-protein kinase (MAPK) within 5-15 minutes, as well as caspase-3 within 24-48 hours. It is noteworthy that ALB6 induced tyrosine phosphorylation of the p46 Shc isoform specifically and that the overexpression of its dominant-negative form completely suppressed the ALB6-induced activation of JNK/SAPK, p38 MAPK and caspase-3, resulting in the inhibition of apoptotic cell death. These results suggest that CD9 might regulate apoptosis through the specialized signals in human cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15226408     DOI: 10.1242/jcs.01201

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  20 in total

1.  Role of CD9 in proliferation and proangiogenic action of human adipose-derived mesenchymal stem cells.

Authors:  Yeon Jeong Kim; Ji Min Yu; Hye Joon Joo; Hoe Kyu Kim; Hyun Hwa Cho; Yong Chan Bae; Jin Sup Jung
Journal:  Pflugers Arch       Date:  2007-08-01       Impact factor: 3.657

2.  Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Bernadette Guerton; Lisa Pieri; Costanza Bogani; Denis Clay; Frederic Torossian; Jean-Jacques Lataillade; Hans C Hasselbach; Heinz Gisslinger; Jean-Loup Demory; Brigitte Dupriez; Claude Boucheix; Eric Rubinstein; Sophie Amsellem; Alessandro M Vannucchi; Marie-Caroline Le Bousse-Kerdilès
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

3.  Functional and biochemical studies of CD9 in fibrosarcoma cell line.

Authors:  Shuli Chen; Yingxia Sun; Zhigao Jin; Xianghong Jing
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

Review 4.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

5.  The C-terminal tail of tetraspanin protein CD9 contributes to its function and molecular organization.

Authors:  Hong-Xing Wang; Tatiana V Kolesnikova; Carilee Denison; Steven P Gygi; Martin E Hemler
Journal:  J Cell Sci       Date:  2011-07-19       Impact factor: 5.285

6.  The tetraspanin superfamily member NET-6 is a new tumor suppressor gene.

Authors:  Huayi Huang; Khalid Sossey-Alaoui; Sarah H Beachy; Joseph Geradts
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

7.  Alveolar type I cells protect rat lung epithelium from oxidative injury.

Authors:  Jiwang Chen; Zhongming Chen; Narendranath Reddy Chintagari; Manoj Bhaskaran; Nili Jin; Telugu Narasaraju; Lin Liu
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

8.  Heparin binding epidermal growth factor-like growth factor and PD169316 prevent apoptosis in mouse embryonic stem cells.

Authors:  Malini Krishnamoorthy; Jamie Heimburg-Molinaro; Ana M Bargo; Rachel J Nash; Rodney J Nash
Journal:  J Biochem       Date:  2008-11-14       Impact factor: 3.387

Review 9.  Targeting of tetraspanin proteins--potential benefits and strategies.

Authors:  Martin E Hemler
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  A novel therapeutic strategy with anti-CD9 antibody in gastric cancers.

Authors:  Taisei Nakamoto; Yoko Murayama; Kenji Oritani; Claude Boucheix; Eric Rubinstein; Makoto Nishida; Fumie Katsube; Kenji Watabe; Shinichi Kiso; Shusaku Tsutsui; Shinji Tamura; Yasuhisa Shinomura; Norio Hayashi
Journal:  J Gastroenterol       Date:  2009-05-26       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.